drug development Related News
Clinical trials: FDA marks psilocybin for depression treatment
The FDA designation represents a major step forward in mental health research and for patients suffering from depression.
A non-profit medical research centre, the Usona...
Artificial Intelligence can design new TB drug regimens
Despite the availability of TB vaccines, 1.5 million people died from TB in 2018.
With a shortage of new tuberculosis drugs in the pipeline, a...
Scientus Pharma: solving drug development challenges for cannabinoid-based drugs
Scientus Pharma have already uncovered areas of remarkable potential with a focus on practical applications, could drug development challenges be solved?
Here, we learn how...
Scientists undertake anorexia psilocybin treatment study
A new wave of scientific research looking at psilocybin could offer promise for the treatment of a number of mental and medical conditions –...
Clinical trials anticipated for treating pancreatic cancer with cannabis
A flavonoid of cannabis – FBL-03G – has been granted Orphan drug status by the United States Food and Drug Administration.
It is anticipated this...
Structure of a novel enzyme linked to cell growth and cancer cracked
A new UC Riverside-led study could lead to the development of drugs that target liver and other cancers.
RNA, or ribonucleic acid, is present in...
Tetra Bio-Pharma: global developer of cannabinoid-derived products
Dr Guy Chamberland explains how Tetra Bio-Pharma is taking a pharmaceutical pathway to discovering and developing cannabinoid-derived products.
In an industry that could aptly be...
More efficient drug delivery within the brain by utilising LAT1
According to a new study carried out at the University of Eastern Finland, drug delivery within the brain can be improved by utilising LAT1,...
Study reveals promising alternative for HIV daily pill regimen
A new study has shown that a long-acting injectable multi-drug implant could offer promise as an alternative for HIV prevention and treatment.
Published in Nature...
Scorpion toxin targeting ‘wasabi receptor’ could help solve mystery of chronic pain
Researchers found a scorpion toxin targeting the 'wasabi receptor', a chemical-sensing protein located in nerve cells responsible for the sinus-jolting sting of wasabi.
At UC...
How pre-filled syringes are helping to deliver the personalised drug revolution
With ‘novel’ biologic and personalised drugs being used to treat and cure chronic ailments, discover how pre-filled syringes are set to gain high traction...
Cancer investigational trials with cannabinoids: Tetra Bio-Pharma will present at the FDA hearing
Today Tetra Bio-Pharma will present key findings from Phase 1 and Phase 2 cancer investigational trials with cannabinoids at the FDA hearing.
The Food and Drug...
PharmaCann International is a welcome new entry in the European cannabis market
PharmaCann International is on the move as Europe is set to witness the world’s fastest evolving and most significant opportunities in the medical cannabis...
Present day use of solvent extraction in cannabis extraction
Organic hydrocarbon solvents offer key benefits in cannabis extraction for patients, manufacturers and policymakers alike.
Organic solvent-based extraction is very common throughout the chemical, food,...
Hyoscine-N-Butyl Bromide may be the new pain management technique
Hyoscine-N-Butyl Bromide can not only be used as a pain management technique, but the market is expected to bring in more than $50 million...
MGC Pharma: Pushing the envelope of phytocannabinoid-based research
Did you know that MGC Pharmaceuticals is creating a seamless seed-to-pharma pipeline of high-quality, pharmaceutical grade phytocannabinoid-based products?
As the world moves into a new...
Developing a first-in-class regenerative gene therapy for cystic fibrosis
OmniSpirant Limited is an Irish company developing a regenerative gene therapy with the potential to transform respiratory medicine.
The innovative OmniSpirant platform is based on...
The artificial pancreas: taking a closer look at type 1 diabetes
JDRF UK chief executive Karen Addington charts progress towards the artificial pancreas, a potentially life-changing technology for people with type 1 diabetes.
Diabetes treatments have...
Aducanumab trials for Alzheimer’s disease stopped early
Pharmaceutical companies Biogen and Eisai announced they are to discontinue two phase III Aducanumab trials of the Alzheimer’s drug.
The ENGAGE and EMERGE trials were...
Treating ovarian cancer may be achieved with a new class of drugs
According to Manchester University, UK, a new class of drugs, called PARG inhibitors, have the ability of treating ovarian cancer and even stopping cancer...